Article

Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP43 proteinopathy

Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Alzheimer's Disease Core Center, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA.
Acta Neuropathologica (Impact Factor: 10.76). 04/2011; 121(4):509-517. DOI: 10.1007/s00401-011-0797-z

ABSTRACT Motor neuron disease (MND) may present as an isolated lower motor neuron (LMN) disorder. Although the significance of pathological
43 kDa transactive responsive sequence DNA binding protein (TDP-43) for amyotrophic lateral sclerosis (ALS) was appreciated
only recently, the topographical distribution of TDP-43 pathology in MND clinically isolated to the LMN versus normal controls
(COs) is only incompletely described. Therefore, we performed longitudinal clinical evaluation and retrospective chart review
of autopsied patients diagnosed with isolated LMN disease. Cases with a disease duration over 4 years were designated as progressive
muscular atrophy (PMA), and those with a more rapid course as MND/LMN. Immunohistochemistry was employed to identify neuronal
and glial TDP-43 pathology in the central nervous system (CNS) in patients and COs. We examined 19 subjects including six
patients (i.e., four with MND/LMN and two with PMA) and 13 COs. All patients showed significant TDP-43 linked degeneration
of LMNs, and five cases showed a lesser degree of motor cortex degeneration. Additional brain areas were affected in varying
degrees, ranging from predominantly brainstem pathology to significant involvement of the whole CNS including neocortical
and limbic areas. Pathological TDP-43 was present only rarely in the CO group. We conclude that MND limited to the LMN and
PMA is part of a disease continuum that includes ALS and FTLD-TDP, all of which are characterized by widespread TDP-43 pathology.
Hence, we suggest that the next revision of the El Escorial criteria for the diagnosis of ALS include MND patients with disease
clinically limited to the LMN and PMA as variants of ALS, which like classical ALS, are TDP-43 proteinopathies.

0 Followers
 · 
86 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Motor neuron degeneration and skeletal muscle denervation are hallmarks of amyotrophic lateral sclerosis (ALS), but other neuron populations and glial cells are also involved in ALS pathogenesis. We examined changes in inhibitory interneurons in spinal cords of the ALS model low-copy Gurney G93A-SOD1 (G1del) mice and found reduced expression of markers of glycinergic and GABAergic neurons, that is, glycine transporter 2 (GlyT2) and glutamic acid decarboxylase (GAD65/67), specifically in the ventral horns of clinically affected mice. There was also loss of GlyT2 and GAD67 messenger RNA-labeled neurons in the intermediate zone. Ubiquitinated inclusions appeared in interneurons before 20 weeks of age, that is, after their development in motor neurons but before the onset of clinical signs and major motor neuron degeneration, which starts from 25 weeks of age. Because mutant superoxide dismutase 1 (SOD1) in glia might contribute to the pathogenesis, we also examined neuron-specific G93A-SOD1 mice; they also had loss of inhibitory interneuron markers in ventral horns and ubiquitinated interneuron inclusions. These data suggest that, in mutant SOD1-associated ALS, pathological changes may spread from motor neurons to interneuronsin a relatively early phase of the disease, independent of the presence of mutant SOD1 in glia. The degeneration of spinal inhibitory interneurons may in turn facilitate degeneration of motor neurons and contribute to disease progression.
    Journal of Neuropathology and Experimental Neurology 08/2011; 70(8):662-77. DOI:10.1097/NEN.0b013e31822581ac · 4.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pathological 43-kDa transactive response sequence DNA-binding protein (TDP-43) has been recognized as the major disease protein in amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with ubiquitin positive, tau and α-synuclein negative inclusions (FTLD-U) and the transitional forms between these multisystem conditions. In order to develop TDP-43 into a successful ALS biomarker, the natural history of TDP-43 pathology needs to be characterized and the underlying pathophysiology established. Here we propose a spatial and temporal "two-axes" model of central nervous system vulnerability for TDP-43 linked degeneration and review recent studies on potential biomarkers related to pathological TDP-43 in the cerebrospinal fluid (CSF), blood, and skeletal muscle. The model includes the following two arms: Firstly, a "motor neuron disease" or "spinal cord/brainstem to motor cortex" axis (with degeneration possibly ascending from the lower motor neurons to the upper motor neurons); and secondly, a "dementia" or "corticoid/allocortex to neocortex" axis (with a probable spread of TDP-43 linked degeneration from the mediotemporal lobe to wider mesocortical and neocortical brain areas). At the cellular level, there is a gradual disappearance of normal TDP-43 in the nucleus in combination with the formation of pathological aggregates in the cell body and cellular processes, which can also be used to identify the stage of the disease process. Moreover, TDP-43 lesions in subpial/subependymal or perivascular localizations have been noted, and this might account for increased CSF and blood TDP-43 levels through mechanisms that remain to be elucidated.
    Progress in Neurobiology 09/2011; 95(4):649-62. DOI:10.1016/j.pneurobio.2011.08.011 · 10.30 Impact Factor
  • Annals of Physical and Rehabilitation Medicine 10/2011; 54. DOI:10.1016/j.rehab.2011.07.183
Show more

Preview

Download
0 Downloads
Available from